Beeline Medicines Initiates First Trial in Lupus Pivotal Development Program with Global Phase 2/3 DISCOVERY Trial of Afimetoran in Cutaneous Lupus Erythematosus (CLE)

– Afimetoran, an investigational oral, once-daily, equipotent TLR7/8 inhibitor, targets a central driver of lupus biology with the potential to address both cutaneous and systemic disease – <p...